Legato Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Legato Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,748	Closed	-$400K	–	694
2026 Q1	$400K	Sell	1,748 -275	-14%	-$61.6K	0.04%	580
2025 Q4	$431K	Buy	2,023 +276	+16%	+$57K	0.04%	611
2025 Q3	$347K	Hold	1,747	–	–	0.04%	479
2025 Q2	$302K	Hold	1,747	–	–	0.04%	497
2025 Q1	$272K	Sell	1,747 -174	-9%	-$24.9K	0.04%	498
2024 Q4	$264K	Buy	1,921 +134	+7%	+$17.6K	0.03%	511
2024 Q3	$267K	Sell	1,787 -2,537	-59%	-$343K	0.03%	518
2024 Q2	$590K	Buy	4,324 +2,708	+168%	+$368K	0.08%	396
2024 Q1	$244K	Hold	1,616	–	–	0.03%	520
2023 Q4	$204K	Buy	+1,616	New	+$161K	0.03%	528
2023 Q1	–	Sell	-2,701	Closed	-$330K	–	500
2022 Q4	$330K	Buy	+2,701	New	+$314K	0.06%	406

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Legato Capital Management's ASND Position: Q2 2026 in Review

Legato Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 1,748 shares — an estimated $400K sold.

Legato Capital Management first reported a position in ASND in Q4 2022 and held it in 11 quarters. The position peaked at $590K in Q2 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Legato Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Legato Capital Management sold 1,748 Ascendis Pharma A/S shares in Q2 2026, an estimated $400K.
Legato Capital Management first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 11 quarters.
Legato Capital Management's Ascendis Pharma A/S position peaked at $590K in Q2 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.